The headline reads as positive (94% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › MDT
Medtronic plc. (MDT) stock analysis
WEAK BUY 30% confidence · analysed Sep 24, 2026
This analysis is from Sep 24, 2026 and may be out of date.
On Sep 24, 2026, our model rated Medtronic plc. (MDT) WEAK BUY with 30% confidence at a price of $89.30. That means the signals lean positive, but they are mixed, so conviction is low.
SectorHealthcare
IndustryMedical Devices
Market cap119.96B
Analysed price$89.30
Technical picture
The 14-day RSI is 39. Momentum is soft: below the neutral 50 line, but not yet oversold.
MACD is below its signal line, so short-term momentum is pointing down.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is about normal (1.2x the 20-day average).
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $103.76 and the swing low is $72.65; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The PEG ratio is 1.63, which looks reasonably priced for its growth.
The company reports a profit margin of 13.9% and revenue growth of +13.7%.
In its latest quarter it earned $1.45 per share, which beat the $1.39 analysts expected, with revenue +13.7% year over year.
Wall Street's average rating is 1.8 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $104.83.
The next earnings report is expected around Nov 17, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $89.70, a target of $94.43 (+5.3%) and a stop-loss at $85.51 (-4.7%).
That is a reward-to-risk ratio of about 1.1 to 1: the potential gain is not much bigger than the loss, so the setup is marginal.
The plan has a time limit: reassess by Oct 4, 2026 whatever the price does.
Entry$89.70
Target$94.43
Stop-loss$85.51
Reassess byOct 4, 2026
The model's one-paragraph read
Leans BUY — composite score +0.30 (WEAK BUY). Technicals: RSI 39.48, MACD bearish, price above SMA50. Fundamentals: PEG 1.63, margin 13.9%, revenue growth 13.7%. Financial results: YoY revenue +13.7%, last EPS surprise +4.3%, next earnings 2026-11-17. Smart Money Concepts: ranging / no clear structure, price retesting a bullish order block. FinGPT news read: positive. Memory: 1 prior look(s); 0% of directional calls matched later price. Suggested levels: entry $89.7, target $94.43, stop-loss $85.51, exit by 2026-10-04 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for MDT
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Sep 24, 2026 | WEAK BUY | 30% | $89.30 | — | |
| Sep 2, 2026 | SKIP | 10% | $93.72 | -4.7% |
"Move since" compares each call's price with the latest analysed price.
Recent news on MDT
Oct 13, 2026 · Medtronic gains after updated research highlights fiscal 2027 guidance and broad segment growth
- Oct 13, 2026: Medtronic gains after updated research highlights fiscal 2027 guidance and broad segment growth (Yahoo Finance)
Other Healthcare stocks we cover
NRC · NVO · OSCR · PCRX · PGNY · PHR · PRGO · SDZNY · SNN · STE · TCMD · TKNO
Frequently asked questions
Is MDT a buy right now?
As of Sep 24, 2026, our automated model rates Medtronic plc. (MDT) WEAK BUY with 30% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for MDT?
The model's most recent plan targets $94.43 with a stop-loss at $85.51, from an entry near $89.70.
When does Medtronic plc. report earnings next?
The next earnings report is expected around Nov 17, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.